Phase III Clinical Trial of TO-194SL - Efficacy and Safety Evaluation in Patients with Japanese Cedar Pollinosis -

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221222

Enrollment

440

Registered

2010-09-01

Start date

2010-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese cedar pollinosis

Interventions

investigational material(s) Generic name etc : TO-194SL INN of investigational material : Therapeutic category code : 449 Other antiallergic agents Dosage and Administration for Investigational mater

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with specific IgE against cedar pollen CAP class 3 or more 2)Patients with clinical history of cedar pollinosis in cedar pollen dispersion season

Exclusion criteria

Exclusion criteria: 1)Patients with complication of nose disease that may interfere with evaluation (nasal polyps, deviation of nasal septum), chronic sinusitis, etc 2)Patients who have developed asthmatic attack within 5 years before the pre-treatment observation visit 3)Patients who have received specific immunotherapy for cedar pollinosis in history 4)Patients with during pregnancy, breast-feeding, possibility of pregnancy or wish to pregnancy during this clinical study period 5)Patients who have participated in any other clinical study or clinical research (including medical equipment study) within 12 weeks before the pre-treatment observation visit

Design outcomes

Primary

Measure	Time frame
Total nasal symptom medication score	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026